FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013462761> ?p ?o ?g. }

• W3013462761 endingPage "e0230489" @default.
• W3013462761 startingPage "e0230489" @default.
• W3013462761 abstract "Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias. The objective of this study is to assess the difference in resistance prevalence between laboratory-based and population-based surveillance (PBS) among uropathogens in Indonesia. We included all urine samples submitted to the laboratory growing Escherichia coli and Klebsiella pneumoniae in the laboratory-based surveillance. Population-based surveillance data were collected in a cross-sectional survey of AMR in E. coli and K. pneumoniae isolated from urine samples among consecutive patients with symptoms of UTI, attending outpatient clinics and hospital wards. Data were collected between 1 April 2014 until 31 May 2015. The difference in percentage resistance (95% confidence intervals) between laboratory- and population-based surveillance was calculated for relevant antibiotics. A difference larger than +/- 5 percent points was defined as a biased result, precluding laboratory-based surveillance for guiding empirical treatment. We observed high prevalence of AMR ranging between 63.1% (piperacillin-tazobactam) and 85% (ceftriaxone) in laboratory-based surveillance and 41.3% (piperacillin-tazobactam) and 74.2% (ceftriaxone) in population-based surveillance, except for amikacin and meropenem (5.7%/9.8%; 10.8%/5.9%; [laboratory-/population-based surveillance], respectively). Laboratory-based surveillance yielded significantly higher AMR prevalence estimates than population-based surveillance. This difference was much larger when comparing surveillance data from outpatients than from inpatients. All point estimates of the difference between the two surveillance systems were larger than 5 percent points, except for amikacin and meropenem. Laboratory-based AMR surveillance of uropathogens, is not adequate to guide empirical treatment for community-based settings in Indonesia." @default.
• W3013462761 created "2020-04-03" @default.
• W3013462761 creator A5009247830 @default.
• W3013462761 creator A5010202448 @default.
• W3013462761 creator A5059234144 @default.
• W3013462761 creator A5063997842 @default.
• W3013462761 creator A5066763131 @default.
• W3013462761 creator A5084030934 @default.
• W3013462761 creator A5085926025 @default.
• W3013462761 date "2020-03-30" @default.
• W3013462761 modified "2023-10-09" @default.
• W3013462761 title "Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia" @default.
• W3013462761 cites W1595882434 @default.
• W3013462761 cites W2120750073 @default.
• W3013462761 cites W2133328739 @default.
• W3013462761 cites W2159479504 @default.
• W3013462761 cites W2581467580 @default.
• W3013462761 cites W2599952066 @default.
• W3013462761 cites W2792891050 @default.
• W3013462761 cites W2810631447 @default.
• W3013462761 cites W2907975440 @default.
• W3013462761 cites W50275070 @default.
• W3013462761 doi "https://doi.org/10.1371/journal.pone.0230489" @default.
• W3013462761 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7105116" @default.
• W3013462761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32226038" @default.
• W3013462761 hasPublicationYear "2020" @default.
• W3013462761 type Work @default.
• W3013462761 sameAs 3013462761 @default.
• W3013462761 citedByCount "8" @default.
• W3013462761 countsByYear W30134627612021 @default.
• W3013462761 countsByYear W30134627612022 @default.
• W3013462761 countsByYear W30134627612023 @default.
• W3013462761 crossrefType "journal-article" @default.
• W3013462761 hasAuthorship W3013462761A5009247830 @default.
• W3013462761 hasAuthorship W3013462761A5010202448 @default.
• W3013462761 hasAuthorship W3013462761A5059234144 @default.
• W3013462761 hasAuthorship W3013462761A5063997842 @default.
• W3013462761 hasAuthorship W3013462761A5066763131 @default.
• W3013462761 hasAuthorship W3013462761A5084030934 @default.
• W3013462761 hasAuthorship W3013462761A5085926025 @default.
• W3013462761 hasBestOaLocation W30134627611 @default.
• W3013462761 hasConcept C104317684 @default.
• W3013462761 hasConcept C126322002 @default.
• W3013462761 hasConcept C2776520383 @default.
• W3013462761 hasConcept C2777058267 @default.
• W3013462761 hasConcept C2777427914 @default.
• W3013462761 hasConcept C2777637488 @default.
• W3013462761 hasConcept C2778193466 @default.
• W3013462761 hasConcept C2778266534 @default.
• W3013462761 hasConcept C2779375183 @default.
• W3013462761 hasConcept C2779631663 @default.
• W3013462761 hasConcept C2908647359 @default.
• W3013462761 hasConcept C501593827 @default.
• W3013462761 hasConcept C523546767 @default.
• W3013462761 hasConcept C54355233 @default.
• W3013462761 hasConcept C547475151 @default.
• W3013462761 hasConcept C55493867 @default.
• W3013462761 hasConcept C71924100 @default.
• W3013462761 hasConcept C86803240 @default.
• W3013462761 hasConcept C89423630 @default.
• W3013462761 hasConcept C94665300 @default.
• W3013462761 hasConcept C99454951 @default.
• W3013462761 hasConceptScore W3013462761C104317684 @default.
• W3013462761 hasConceptScore W3013462761C126322002 @default.
• W3013462761 hasConceptScore W3013462761C2776520383 @default.
• W3013462761 hasConceptScore W3013462761C2777058267 @default.
• W3013462761 hasConceptScore W3013462761C2777427914 @default.
• W3013462761 hasConceptScore W3013462761C2777637488 @default.
• W3013462761 hasConceptScore W3013462761C2778193466 @default.
• W3013462761 hasConceptScore W3013462761C2778266534 @default.
• W3013462761 hasConceptScore W3013462761C2779375183 @default.
• W3013462761 hasConceptScore W3013462761C2779631663 @default.
• W3013462761 hasConceptScore W3013462761C2908647359 @default.
• W3013462761 hasConceptScore W3013462761C501593827 @default.
• W3013462761 hasConceptScore W3013462761C523546767 @default.
• W3013462761 hasConceptScore W3013462761C54355233 @default.
• W3013462761 hasConceptScore W3013462761C547475151 @default.
• W3013462761 hasConceptScore W3013462761C55493867 @default.
• W3013462761 hasConceptScore W3013462761C71924100 @default.
• W3013462761 hasConceptScore W3013462761C86803240 @default.
• W3013462761 hasConceptScore W3013462761C89423630 @default.
• W3013462761 hasConceptScore W3013462761C94665300 @default.
• W3013462761 hasConceptScore W3013462761C99454951 @default.
• W3013462761 hasIssue "3" @default.
• W3013462761 hasLocation W30134627611 @default.
• W3013462761 hasLocation W30134627612 @default.
• W3013462761 hasLocation W30134627613 @default.
• W3013462761 hasLocation W30134627614 @default.
• W3013462761 hasOpenAccess W3013462761 @default.
• W3013462761 hasPrimaryLocation W30134627611 @default.
• W3013462761 hasRelatedWork W2072573137 @default.
• W3013462761 hasRelatedWork W2367213826 @default.
• W3013462761 hasRelatedWork W2892368225 @default.
• W3013462761 hasRelatedWork W2919702677 @default.
• W3013462761 hasRelatedWork W2995046922 @default.
• W3013462761 hasRelatedWork W3047018695 @default.
• W3013462761 hasRelatedWork W4232636985 @default.
• W3013462761 hasRelatedWork W4236551697 @default.

• next